BiotechTube

Exenatide + Metformin

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Impaired Glucose Tolerance

Conditions

Impaired Glucose Tolerance

Trial Timeline

Oct 1, 2007 → Jul 1, 2011

NCT ID
NCT00546728

About Exenatide + Metformin

Exenatide + Metformin is a approved stage product being developed by Eli Lilly for Impaired Glucose Tolerance. The current trial status is completed. This product is registered under clinical trial identifier NCT00546728. Target conditions include Impaired Glucose Tolerance.

What happened to similar drugs?

2 of 4 similar drugs in Impaired Glucose Tolerance were approved

Approved (2) Terminated (1) Active (2)
✅Immediate switch to TDF/FTC/RPV + Switch to TDF/FTC/RPV after 24 weeksGilead SciencesApproved
✅Gabapentin + Gabapentin + Gabapentin + GabapentinPfizerApproved
🔄balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg + balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg + dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozinAstraZenecaPhase 3
🔄Ramipril + RosiglitazonePfizerPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00546728ApprovedCompleted

Competing Products

19 competing products in Impaired Glucose Tolerance

See all competitors
ProductCompanyStageHype Score
Aspirin + Alpha lipoic acid + Olmesartan + PlaceboDaiichi SankyoPre-clinical
26
ASP8825Astellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
GilteritinibAstellas PharmaPhase 1
29
fospropofol + fospropofol + fospropofol + fospropofolEisaiPre-clinical
18
Apatinib MesylateJiangsu Hengrui MedicinePhase 1
25
balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg + balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg + dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozinAstraZenecaPhase 3
47
Tetanus & Diphtheria booster vaccine (Td) + TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine] + Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)MerckPre-clinical
26
ASA404NovartisPhase 1
21
MAS825 + Standard of Care (SoC)NovartisPhase 2
35
DFV890 + Standard of Care (SoC)NovartisPhase 2
35
Immediate switch to TDF/FTC/RPV + Switch to TDF/FTC/RPV after 24 weeksGilead SciencesApproved
43
Gabapentin + Gabapentin + Gabapentin + GabapentinPfizerApproved
35
Ramipril + RosiglitazonePfizerPhase 3
40
HSK7653 10mg Q2W + HSK7653 25mg Q2W + PlaceboHaisco Pharmaceutical GroupPhase 2
35
NBI-98854 50 mg capsuleNeurocrine BiosciencesPhase 1
26
BIS-001ERSupernus PharmaceuticalsPhase 1/2
30
GFT505 80mg + PlaceboGenfitPhase 2
25